🇺🇸 FDA
Pipeline program

Gilteritinib

2215-CL-5101

Phase 2 small_molecule terminated

Quick answer

Gilteritinib for Non-Small-Cell Lung Cancer is a Phase 2 program (small_molecule) at Astellas Pharma Inc with 1 ClinicalTrials.gov record(s).

Program details

Company
Astellas Pharma Inc
Indication
Non-Small-Cell Lung Cancer
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials